Table 2

Clinical trials evaluating new approaches focused on early cancer detection through screening

NCT	Sponsor	Trial name	Estimated enrollment	Biomarker	Condition	Age eligibility (years)	Status
NCT05366881	Adela	CAMPERR	7,000	cfDNA	MCED	≥40	Recruiting
NCT04972201	Burning Rock	PROMISE	2,305	cfNA	MCED	40–75	Recruiting
NCT03869814	ClearNote Health	MT1410	6,500	5-hmC ctDNA	MCED	45–75	Recruiting
NCT04825834	DELFI Diagnostics	L101	2,500	ctDNA	Lung cancer	≥50	Recruiting
NCT05306288	DELFI Diagnostics	CASCADE	15,000	ctDNA	Lung cancer	≥50	Recruiting
NCT04144751	Exact Sciences	Blue-C	24,000	Blood-based	Colorectal cancer	≥40	Active, not recruiting
NCT04369053	Freenome	Preempt	25,000	ctDNA	Colorectal cancer	45–84	Active, not recruiting
NCT05516927	Freenome	Sanderson Study	8,000	Multiomics	MCED	≥30	Recruiting
NCT05227261	Gene Solutions	K-DETEK	3,000	ctDNA	Lung, breast, liver, colorectal, and gastric cancers	≥40	Recruiting
ISRCTN10226380	Grail	SYMPLIFY	6,238	cfDNA	MCED in symptomatic individuals	≥18	Completed
NCT04241796	Grail	Pathfinder	6,662	ctDNA	MCED	≥50	Completed
NCT03085888	Grail	Strive	99,481	cfNA	MCED	≥18	Active, not recruiting
NCT03934866	Grail/UCL	Summit	13,035	cfNA	Lung cancer	55–77	Active, not recruiting
NCT03774758	Guardant Health	17–22915	590	ctDNA	Lung cancer	≥40	Recruiting
NCT04136002	Guardant Health	Eclipse	20,000	ctDNA	Colorectal cancer	45–84	Recruiting
NCT05181826	Helio Health	ELITE	1,200	ctDNA	Cancer-free, benign, cancer	≥18	Recruiting
NCT05199259	Helio Health	Liver-1	1,200	ctDNA	Hepatocellular carcinoma	≥18	Recruiting
NCT03694600	Helio Health	CLiMB	1,600	cfDNA	Liver cirrhosis, hepatocellular carcinoma	21–84	Recruiting
NCT05432128	Singlera Genomics	2019YFC1315803	600	ctDNA	Lung cancer	18–75	Recruiting
NCT05485077	Singlera Genomics	KYS-2022007	18,000	cfDNA	Colorectal cancer	≥40	Recruiting

cfDNA, cell-free DNA; cfNA, cell-free nucleic acids; ctDNA, circulating tumor-derived DNA; MCED, multi-cancer early detection.